ClinicalTrials.gg
RecruitingNCT07176000Updated Oct 27, 2026

Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial

An interventional study of Patient Navigation and Educational Intervention in Lung Carcinoma, sponsored by Fred Hutchinson Cancer Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center — 6 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Fred Hutchinson Cancer Center.

Planned enrollment
4th of 12
237 · median 52
Started
2026
with 3 others
No phase
8 of 13
4 open now
Registered
10th of 13
by date

Among the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 with no phase, and was the 10th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial studies whether tailored patient navigation (PN) works to improve the uptake of lung cancer screening (LCS) in tribal communities in western Washington state. Lung cancer is the leading cause of cancer death in the United States among American Indian (AI) and Alaska Native (AN) people, and the incidence of lung cancer is higher in this population in the Northern and Southern Plains, Alaska, and Pacific Coast regions. In Washington state, AI/AN people also have twice the rate of commercial cigarette smoking than the overall population. LCS with annual low-dose chest computed tomography (CT) can reduce lung cancer death and is recommended in people 50-80 years of age with current or recent (within 15 years) tobacco use and a 20 pack-year or greater smoking history. Despite this, AI and AN people are less likely to receive LCS which may be due to barriers they face making it difficult to receive LCS. PN services are designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The PN services in this trial have been tailored for the tribal communities in western Washington state. The services are designed to help participants overcome the unique barriers that their tribal communities face and improve the uptake of LCS.

Read the detailed description

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM 1: Participants receive tailored PN activities in support of the uptake and follow-up of LCS for 21 months. Participants also receive an educational handout on LCS on study.

ARM 2: Participants receive enhanced usual care consisting of an educational handout on LCS and a warm hand-off to discuss LCS with their primary care physician (PCP) for 6 months. Participants then receive tailored PN services in support of the uptake and follow-up of LCS for 15 months.

03

Conditions studied

  • Lung Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Between ages 50-77
  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Self-reported 20-pack year smoking history
  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Ongoing commercial tobacco use within the past 15 years
  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Seen by a PCP at a participating clinic (South Puget Intertribal Planning Agency [SPIPA] or Muckleshoot) within the past three years

    • Potential participants who want to establish care at an eligible clinic will be connected to a PCP
  • AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age
  • AIM 2 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member
  • AIM 2 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial
  • AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: At least 18 years of age
  • AIM 3 CLINICAL STAFF SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Affiliation with Muckleshoot or SPIPA (one of the 6 community partnering clinics) as a provider, or supportive staff member
  • AIM 3 PATIENT SURVEYS AND SEMI-STRUCTURED INTERVIEWS: Patient participated in the aim 1.2 trial

Exclusion criteria

Exclusion Criteria:

  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Has had a documented chest CT within the past one year
  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Personal history of lung cancer
  • AIM 1.2 RANDOMIZED CONTROLLED TRIAL: Personal history of any cancer within 5 years except for basal cell or squamous cell skin carcinoma
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
237 participants (estimated)

Study arms

  • Experimental
    Arm 1 (tailored PN)

    Participants receive tailored PN activities in support of the uptake and follow-up of LCS for 21 months. Participants also receive an educational handout on LCS on study.

    Behavioral: Patient Navigation · Other: Educational Intervention · Other: Interview · Other: Survey Administration · Other: Electronic Health Record Review

  • Active comparator
    Arm 2 (enhanced usual care, delayed tailored PN)

    Participants receive enhanced usual care consisting of an educational handout on LCS and a warm hand-off to discuss LCS with their PCP for 6 months. Participants then receive tailored PN services in support of the uptake and follow-up of LCS for 15 months.

    Behavioral: Patient Navigation · Other: Best Practice · Other: Interview · Other: Survey Administration · Other: Electronic Health Record Review

Interventions

  • BehavioralPatient Navigation

    Receive tailored PN activities

    Also known as: Patient Navigator Program

  • OtherEducational Intervention

    Receive LCS educational handout

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherBest Practice

    Receive enhanced usual care

    Also known as: standard of care, standard therapy

  • OtherInterview

    Ancillary studies

  • OtherSurvey Administration

    Ancillary studies

  • OtherElectronic Health Record Review

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Completion of chest computed tomography (CT) (Aim 1.2)

    Will be compared between arms using the Cochran-Mantel-Haenszel (CMH) test, accounting for the stratification variables used during randomization. Completion rates will also be estimated in each arm and 95% confidence intervals for the rates and their difference will be calculated using Wilson's score method. The single primary outcome will be tested using two-sided α = 0.05.

    Time frame: Up to 6 months

Secondary outcomes

  1. Completion of low dose computed tomography of the chest (Aim 1.2)

    Will be compared between arms using the CMH test. Will be tested using two-sided α = 0.05 without adjustment for multiplicity.

    Time frame: Up to 21 months

  2. Lung cancer screening (LCS) knowledge (Aim 1.2)

    Will be compared between arms using a stratified Wilcoxon rank-sum test (van Elteren test). Will be tested using two-sided α = 0.05 without adjustment for multiplicity.

    Time frame: At 21 months

  3. Health-related quality of life (Aim 1.2)

    Will be measured using the Short Form 36 Health Survey questionnaire. Will be compared between arms using a stratified Wilcoxon rank-sum test (van Elteren test). Will be tested using two-sided α = 0.05 without adjustment for multiplicity.

    Time frame: At 21 months

  4. Rate of reported 30-day cessation period (Aim 1.2)

    The impact of navigation on tobacco cessation will be explored by the rates of a reported 30-day cessation period during the intervention period as measured by self-reported 30-day floating abstinence.

    Time frame: Up to 6 months

  5. Completion of chest CT (Aim 2)

    Quantitative analyses will use structural equation models (SEM) to understand the relationships between measured and latent variables representing barriers, facilitators and social determinants of health and the outcome of CT completion.

    Time frame: Up to 6 months

  6. Navigation care engagement (Aim 2)

    Quantitative analyses in this aim will use SEM to understand the relationships between measured and latent variables representing barriers, facilitators and social determinants of health and the outcome of navigation care engagement. Measure of reach will be operationalized as an ordinal scale based on care completion activities along the LCS continuum as documented in the electronic health record.

    Time frame: Up to 21 months

  7. Completion of chest CT (Aim 3)

    The rate of chest CT completion during the maintenance phase in the control arm (after navigation is offered) will be estimated and compared with the rate during the trial phase (before navigation was offered) using Poisson regression with the log link. The phase (trial versus maintenance) will be modeled using a time varying covariate, where each participant will contribute an outcome for each phase in which they are still "at risk" for completing CT (i.e., until first CT completion or end of follow-up). Models will include additional key covariates, including clinical site, smoking status, and prior reported LCS. Generalized estimating equations will be used to account for multiple periods per participant and potential overdispersion.

    Time frame: Up to 15 months

  8. Completion of next diagnostic step in LCS follow-up

    Adherence to follow-up will be assessed as binary completion of the next step in follow-up among those with a completed chest CT during the randomized controlled trial. Appropriate next step in follow-up is determined through the Lung CT Screening Reporting and Data System (Lung-RADS) system, with most participants having negative initial CT (Lung-RADS 1 or 2) with follow-up assessed at 11-15 months. Adherence rates will be estimated as a proportion with 95% confidence intervals, summarized overall and stratified by Lung-RADS.

    Time frame: Up to 15 months

07

Study locations

2 of 2 sites recruiting
  • Muckleshoot Tribal Clinic
    Auburn, Washington 98092, United States
    Recruiting
  • South Puget Intertribal Planning Agency (SPIPA)
    Shelton, Washington 98584, United States
    Recruiting
08

References and documents

Publications

  • Triplette M, Walsh C, Shah PD, Hippe DS, Louie T, Anderson N, Long S, Omernik B, Schwartz J, Nelson L, Parker M, Mendoza JA, Nikander J, Ramachandran M, Carey A, Tsosie U. Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol. Contemp Clin Trials. 2026 Sep;168:108408. doi: 10.1016/j.cct.2026.108408. Epub 2026 Jul 20. PubMed 42476254 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 29 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Oct 1, 2026
Primary completionEst.
Mar 29, 2029
CompletionEst.
Apr 30, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Oct 1, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Oct 15, 2026→Oct 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07176000
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Oct 1, 2026
Primary completion
Mar 29, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Matty Triplette, MD, MPH
Contact
mtriplet@fredhutch.org
(206) 667-6335
Matty Triplette, MD, MPH
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion